ArticleCell reports2022
Immune correlates of HIV-1 reservoir cell decline in early-treated infants.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02369406 (BHP Early Infant Treatment Study), which is not on this map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana
Who cites it
34 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.Science translational medicine · 2023Trial
- How past transient viremia shape natural killer cells' antibody-dependent functions in youth with perinatal HIV.iScience · 2026Article
- Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.Current opinion in HIV and AIDS · 2026Review
- The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- NK cell dysregulation may potentiate cardiovascular disease in adolescents with perinatally acquired HIV on antiretroviral therapy.Nature communications · 2026Article
- Dynamics of Intact and Defective Human Immunodeficiency Virus Type 1 (HIV-1) Proviruses During Decades of Suppressive Antiretroviral Treatment in Young Adults With Perinatal HIV.The Journal of infectious diseases · 2026Article
- Elimination of Human Immunodeficiency Virus Reservoirs Harboring Intact Proviruses.The Journal of infectious diseases · 2026Article
- Immune correlates of HIV-1 rebound during broadly neutralizing antibody treatment in young children.The Journal of clinical investigation · 2026Article
- NK Cells Engineered with a Chimeric Antigen Receptor Delay HIV Rebound and Reshape HIV Reservoir Composition.bioRxiv : the preprint server for biology · 2026Article
- A role for Fas/FasL-dependent NK-mediated cytotoxicity in infants with perinatal HIV.iScience · 2025Article
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1.Cell reports. Medicine · 2025Article
- Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention.Current opinion in HIV and AIDS · 2025Review
- Intact HIV DNA decays in children with and without complete viral load suppression.PLoS pathogens · 2025Article
- Persistent elite controllers as the key model to identify permanent HIV remission.Current opinion in HIV and AIDS · 2025Review
- Monocytes across life span in HIV infection: lights and shadows.Current opinion in HIV and AIDS · 2025Review
- HIV cure research contributions from Africa in the last three decades.Frontiers in immunology · 2025Review
- Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment.Virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 1 country.
Ciputra Adijaya HartanaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Pilar Garcia-BroncanoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Yelizaveta RassadkinaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Xiaodong LianRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Chenyang JiangRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Kevin B EinkaufRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Kenneth MaswabiBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Gbolahan AjibolaBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile MoyoBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Terence MohammedBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Comfort MaphorisaBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph MakhemaBotswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Yuko YukiBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Maureen MartinBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Kara BennettBennett Statistical Consulting, Inc., Ballston Lake, NY 12019, USA.
Patrick Jean-PhilippeDivision of AIDS, NIAID, NIH, Rockville, MD 20852, USA.
Mathias ViardBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Michael D HughesDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Kathleen M PowisHarvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Shahin LockmanDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.
Ce GaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Roger ShapiroHarvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: mlichterfeld@partners.org.
Ragon Institute of MGH, MIT and Harvard · USHarvard University · USOffice of AIDS Research · USStatistical Research (United States) · US
Funding
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5MA Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7MA clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4MMolecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8MEarly Infant TreatmentU01AI114235 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2014 to 2020
$5.1MImmunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1MNovel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1MSelection and Evolution of HIV-1 reservoir cells in blood and tissuesR01AI152979 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ESTES, JACOB D, LICHTERFELD, MATHIAS · 2020 to 2025
$3.8MMolecular profile of proviral reservoirs in HIV-infected drug usersR61DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2018 to 2020
$3.4MA systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3MMolecular profile of proviral reservoirs in HIV-infected drug usersR33DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2022 to 2024
$2.0MQuantification of the HIV-1 Reservoir by Immuno-PCRR01AI120008 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HEREDIA, ALONSO, LICHTERFELD, MATHIAS · 2015 to 2019
$1.9MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENHLBI NIH HHS R01 HL134539NIAID NIH HHS K24 AI155233NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI098487NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI152979NIAID NIH HHS R21 AI116228NIAID NIH HHS R21 AI120850NIAID NIH HHS R33 AI116228NIAID NIH HHS R56 AI125109NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI135940NIAID NIH HHS UM1 AI164566NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIDDK NIH HHS R01 DK120387
Abstract
Initiation of antiretroviral therapy (ART) in infected neonates within hours after birth limits viral reservoir seeding but does not prevent long-term HIV-1 persistence. Here, we report parallel assessments of HIV-1 reservoir cells and innate antiviral immune responses in a unique cohort of 37 infected neonates from Botswana who started ART extremely early, frequently within hours after birth. Decline of genome-intact HIV-1 proviruses occurs rapidly after initiation of ART and is associated with an increase in natural killer (NK) cell populations expressing the cytotoxicity marker CD57 and with a decrease in NK cell subsets expressing the inhibitory marker NKG2A. Immune perturbations in innate lymphoid cells, myeloid dendritic cells, and monocytes detected at birth normalize after rapid institution of antiretroviral therapy but do not notably influence HIV-1 reservoir cell dynamics. These results suggest that HIV-1 reservoir cell seeding and evolution in early-treated neonates is markedly influenced by antiviral NK cell immune responses.
Indexed as
HIV-1HIV InfectionsHIV SeropositivityAntiviral AgentsCD4-Positive T-LymphocytesHumansImmunity, InnateInfant, NewbornKiller Cells, NaturalAntiviral AgentsCP: ImmunologyCP: MicrobiologyHIV reservoirinnate immune responsesintact HIV-1 provirusesNK cellspediatric HIV-1 infection
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02369406ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.